Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:DAWN NASDAQ:IMTX NASDAQ:TLSA NASDAQ:TNGX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDAWNDay One Biopharmaceuticals$7.12-3.4%$6.89$5.64▼$16.76$754.92M-1.251.05 million shs671,274 shsIMTXImmatics$5.82-1.7%$5.98$3.30▼$13.09$719.58M1.02807,553 shs699,404 shsTLSATiziana Life Sciences$1.69-5.6%$1.86$0.63▼$2.60$209.16M-0.36301,027 shs655,336 shsTNGXTango Therapeutics$6.53-4.5%$6.60$1.03▼$10.85$761.02M1.641.34 million shs1.78 million shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDAWNDay One Biopharmaceuticals-3.39%-5.70%+14.65%+6.75%-49.47%IMTXImmatics-1.69%-7.03%-4.59%-4.90%-50.21%TLSATiziana Life Sciences-5.59%+1.81%-20.66%+9.03%+92.05%TNGXTango Therapeutics-4.53%-5.91%-5.09%+39.23%-32.61%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDAWNDay One Biopharmaceuticals$7.12-3.4%$6.89$5.64▼$16.76$754.92M-1.251.05 million shs671,274 shsIMTXImmatics$5.82-1.7%$5.98$3.30▼$13.09$719.58M1.02807,553 shs699,404 shsTLSATiziana Life Sciences$1.69-5.6%$1.86$0.63▼$2.60$209.16M-0.36301,027 shs655,336 shsTNGXTango Therapeutics$6.53-4.5%$6.60$1.03▼$10.85$761.02M1.641.34 million shs1.78 million shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDAWNDay One Biopharmaceuticals-3.39%-5.70%+14.65%+6.75%-49.47%IMTXImmatics-1.69%-7.03%-4.59%-4.90%-50.21%TLSATiziana Life Sciences-5.59%+1.81%-20.66%+9.03%+92.05%TNGXTango Therapeutics-4.53%-5.91%-5.09%+39.23%-32.61%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDAWNDay One Biopharmaceuticals 3.13Buy$25.29255.14% UpsideIMTXImmatics 2.83Moderate Buy$14.67152.00% UpsideTLSATiziana Life Sciences 0.00N/AN/AN/ATNGXTango Therapeutics 3.00Buy$10.5060.80% UpsideCurrent Analyst Ratings BreakdownLatest TLSA, DAWN, TNGX, and IMTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/18/2025DAWNDay One BiopharmaceuticalsPiper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$25.008/18/2025TNGXTango TherapeuticsPiper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$11.008/15/2025IMTXImmaticsZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell8/6/2025DAWNDay One BiopharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$18.00 ➝ $16.008/6/2025DAWNDay One BiopharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$36.00 ➝ $25.008/6/2025TNGXTango TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$8.00 ➝ $10.00(Data available from 9/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDAWNDay One Biopharmaceuticals$131.16M5.56N/AN/A$4.99 per share1.43IMTXImmatics$130.13M5.44$0.24 per share24.23$5.12 per share1.14TLSATiziana Life SciencesN/AN/AN/AN/A$0.04 per shareN/ATNGXTango Therapeutics$42.07M17.27N/AN/A$1.86 per share3.51Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDAWNDay One Biopharmaceuticals-$95.50M-$0.95N/AN/AN/A-50.63%-19.01%-16.99%10/29/2025 (Estimated)IMTXImmatics$16.47M-$0.65N/AN/AN/A-59.29%-15.60%-12.31%11/17/2025 (Estimated)TLSATiziana Life Sciences-$11.86MN/A0.00∞N/AN/AN/AN/A10/13/2025 (Estimated)TNGXTango Therapeutics-$130.30M-$1.33N/AN/AN/A-599.11%-79.72%-49.30%11/5/2025 (Estimated)Latest TLSA, DAWN, TNGX, and IMTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q1 2025IMTXImmatics-$0.38-$0.66-$0.28-$0.66$13.05 million$6.48 million8/5/2025Q2 2025DAWNDay One Biopharmaceuticals-$0.35-$0.29+$0.06-$0.29$35.55 million$33.91 million8/5/2025Q2 2025TNGXTango Therapeutics-$0.35-$0.35N/A-$0.35$6.41 million$3.18 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthDAWNDay One BiopharmaceuticalsN/AN/AN/AN/AN/AIMTXImmaticsN/AN/AN/AN/AN/ATLSATiziana Life SciencesN/AN/AN/AN/AN/ATNGXTango TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDAWNDay One BiopharmaceuticalsN/A9.659.53IMTXImmaticsN/A8.808.80TLSATiziana Life SciencesN/A1.021.02TNGXTango TherapeuticsN/A4.754.75Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDAWNDay One Biopharmaceuticals87.95%IMTXImmatics64.41%TLSATiziana Life SciencesN/ATNGXTango Therapeutics78.99%Insider OwnershipCompanyInsider OwnershipDAWNDay One Biopharmaceuticals6.20%IMTXImmatics3.30%TLSATiziana Life Sciences39.82%TNGXTango Therapeutics7.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDAWNDay One Biopharmaceuticals60102.43 million96.08 millionOptionableIMTXImmatics260121.55 million117.54 millionOptionableTLSATiziana Life Sciences8116.85 million70.32 millionOptionableTNGXTango Therapeutics90111.26 million102.92 millionOptionableTLSA, DAWN, TNGX, and IMTX HeadlinesRecent News About These CompaniesTango Therapeutics (NASDAQ:TNGX) Trading Down 6.7% on Insider SellingSeptember 12 at 1:42 PM | marketbeat.comTango Therapeutics (NASDAQ:TNGX) Stock Price Down 6.7% After Insider SellingSeptember 12 at 2:23 AM | americanbankingnews.comTango Therapeutics (NASDAQ:TNGX) Major Shareholder Sells $608,671.36 in StockSeptember 11 at 5:43 PM | marketbeat.comRock Ventures Iv L.P. Third Sells 642,906 Shares of Tango Therapeutics (NASDAQ:TNGX) StockSeptember 11 at 5:42 PM | marketbeat.comInsider Selling: Tango Therapeutics (NASDAQ:TNGX) Major Shareholder Sells 86,459 Shares of StockSeptember 10 at 6:00 AM | insidertrades.comTango Therapeutics, Inc. $TNGX Stake Cut by American Century Companies Inc.September 9, 2025 | marketbeat.comNuveen LLC Purchases New Shares in Tango Therapeutics, Inc. $TNGXSeptember 8, 2025 | marketbeat.comWalleye Capital LLC Sells 75,255 Shares of Tango Therapeutics, Inc. $TNGXSeptember 6, 2025 | marketbeat.comRussell Investments Group Ltd. Buys 49,116 Shares of Tango Therapeutics, Inc. $TNGXSeptember 6, 2025 | marketbeat.comTango Therapeutics (NASDAQ:TNGX) Trading Down 5.1% - Time to Sell?September 5, 2025 | marketbeat.comADAR1 Capital Management LLC Makes New Investment in Tango Therapeutics, Inc. $TNGXSeptember 5, 2025 | marketbeat.comNantahala Capital Management LLC Acquires 183,573 Shares of Tango Therapeutics, Inc. $TNGXSeptember 3, 2025 | marketbeat.comSiren L.L.C. Sells 38,555 Shares of Tango Therapeutics, Inc. $TNGXAugust 31, 2025 | marketbeat.comAlgert Global LLC Cuts Position in Tango Therapeutics, Inc. $TNGXAugust 28, 2025 | marketbeat.comRock Ventures Iv L.P. Third Sells 302,194 Shares of Tango Therapeutics (NASDAQ:TNGX) StockAugust 27, 2025 | insidertrades.comTango Therapeutics to Participate in the 2025 Cantor Global Healthcare ConferenceAugust 26, 2025 | globenewswire.comTango Therapeutics (NASDAQ:TNGX) Major Shareholder Sells $7,711,000.00 in StockAugust 22, 2025 | insidertrades.comTango Therapeutics, Inc. (NASDAQ:TNGX) Given Consensus Rating of "Buy" by BrokeragesAugust 20, 2025 | marketbeat.comPiper Sandler Initiates Coverage of Tango Therapeutics (TNGX) with Overweight RecommendationAugust 19, 2025 | msn.comTango Therapeutics initiated with an Overweight at Piper SandlerAugust 19, 2025 | msn.comPiper starts Tango Therapeutics with an Overweight on TNG462 potentialAugust 19, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTLSA, DAWN, TNGX, and IMTX Company DescriptionsDay One Biopharmaceuticals NASDAQ:DAWN$7.12 -0.25 (-3.39%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$7.12 0.00 (-0.07%) As of 09/12/2025 04:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.Immatics NASDAQ:IMTX$5.82 -0.10 (-1.69%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$5.88 +0.05 (+0.95%) As of 09/12/2025 06:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes IMA203 that targets solid tumors, which is in Phase 1b clinical trial; IMA203CD8, a cell therapy product that is in Phase 1b clinical trial; IMA204 that targets tumor stroma, which is in preclinical stage; and IMA30x, an allogenic cellular therapy product candidate, which is in preclinical stage. The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.Tiziana Life Sciences NASDAQ:TLSA$1.69 -0.10 (-5.59%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$1.67 -0.02 (-1.18%) As of 09/12/2025 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It also develops Milciclib (TZLS-201), a small molecule inhibitor of various cyclin-dependent kinases, tropomycin receptor kinases, and Src family kinases controlling cell growth and malignant progression of cancer; and anti- receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody for the treatment of IL6-induced inflammation and to treat COVID-19 patients. Tiziana Life Sciences Ltd was incorporated in 1998 and is headquartered in London, the United Kingdom.Kingdom.Tango Therapeutics NASDAQ:TNGX$6.53 -0.31 (-4.53%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$6.60 +0.07 (+1.07%) As of 09/12/2025 05:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company develops TNG462, an oral small molecule methylthioadenosine-cooperative inhibitor for the treatment for cancers with methylthioadenosine phosphorylase deletions; TNG260, a co-repressor of repressor element-1 silencing transcription -selective inhibitor; TNG348, an ubiquitin-specific protease 1 inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. It has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. Tango Therapeutics, Inc. was founded in 2017 and is headquartered in Boston, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 09/08 - 09/12 Meta's $600B U.S. Investment: Bearish or Bullish for Shares? Post Onum Deal: Is CrowdStrike Ready to Rebound After 16% Drop? Chewy’s September Pullback: Is It Your Time to Buy? It’s Time to Buy the Dip in Kroger Stock Price Is Coupang the Next MercadoLibre? A Playbook for Global Dominance Vanguard’s VUG ETF: The Ultimate Growth ETF for Your Portfolio Tesla's U.S. Market Is At An 8-Year Low... How Bad Could It Get? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
